EV
Evaxion Biotech A/S
EVAX · NASDAQ
$3.10 -5.05% (-$0.17)
1M +0.98%
Market Cap $19.6M
P/E Ratio -
Div. Yield -
ROE 61.39%
Bulios Fair Price
$4.04
30.3% upside
Trenutna cena
$3.1
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica EVAX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
5/9Valuation
76 /100
Cheap P/B 2.05x
P/S 2.61x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 27.08%
FCF growth N/A
EPS growth N/A
Profitability
22 /100
Weak Op. margin 115.98%
Gross margin 100.00%
FCF margin 0.00%
Quality
5 /100
Poor ROA 44.65%
ROIC 46.68%
Asset turnover 0.39x
Debt
54 /100
Moderate Int. coverage -13.58x
Debt/Equity 0.75x
Current ratio 5.06x
Stability
31 /100
Unstable Profitable years 0
Beta 0.27x
EPS volatility 36.54%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o EVAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Katrina Tayton-Martin
Employees
46
Headquarters
Horsholm
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report